Vedolizumab response in inflammatory bowel disease: Two years of follow-up

• Pilar del Pino Bellido ^[1] ; María Belvis Jiménez ^[1] ; Luisa Castro Laria ^[1] ; María Belén Maldonado Pérez ^[1] ; Antonia Sáez Díaz ^[1] ; Ángel Caunedo Álvarez ^[1] ; Federico Argüelles-Arias ^[1]
  1. [1] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
• Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 112, Nº. 7, 2020, págs. 555-558
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. Methods: this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction. Results: fifty-five patients were included. Clinical remission rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively. Conclusions: vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn’s disease and ulcerative colitis.